The approval is supported by data from clinical trials, including pharmacodynamic and pharmacokinetic responses in adults and ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Celon Pharma’s PDE10A inhibitor has reduced involuntary movements in a phase 2 trial of individuals with Parkinson’s disease.

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...

Antibiotic therapy relies on understanding both pharmacokinetics (PK) and pharmacodynamics (PD), which respectively address drug absorption, distribution, and elimination, and the relationship between ...

AvailTM trial exceeded enrollment target; topline results expected in Q3 2025CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- ...

Q4 2024 Earnings Call Transcript March 4, 2025 Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

在非小细胞肺癌（NSCLC）患者中，原发 MET 扩增较为少见，且与不良预后相关[1]。随着 MET 抑制剂的问世和临床研究的不断探索，为原发 MET 扩增 NSCLC 患者带来了新的治疗希望。本期「In China For Global - MET ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

Dr. Chris VanDeusen, Chief Scientific Officer, will present “TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Dermatologic Diseases,” ...

Introduction: The establishment of clinical breakpoints for antimicrobial drug is crucial for guiding appropriate therapeutic interventions. This study aims to ...